While dysregulated expression has been observed on the surface of malignant cells and infiltrating leukocytes—most notably dendritic cells—in both malignancies, the mechanisms driving aberrant overexpression of BTN3A1 in cancer remain unknown [16,17]. The gene discussed is BTN3A1; the disease is cancer.